Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04764383 (ClinicalTrials.gov)	January 1, 2022	18/2/2021	Histaminergic Basis of Fatigue in Multiple Sclerosis	Histaminergic Basis of Fatigue in Multiple Sclerosis	Multiple Sclerosis	Drug: L-Histidine;Drug: Placebo;Drug: Lodosyn	University of Miami	NULL	Withdrawn	18 Years	60 Years	All	0	Phase 2	United States
2	NCT03266965 (ClinicalTrials.gov)	March 23, 2018	4/7/2017	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Multiple Sclerosis	Drug: Carbidopa;Dietary Supplement: L-Histidine	University of Miami	United States Department of Defense	Completed	18 Years	60 Years	All	18	Phase 1	United States
3	NCT00630383 (ClinicalTrials.gov)	February 2008	27/2/2008	Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.	Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.	Multiple Sclerosis	Biological: Live Hookworm Larvae;Other: Histamine	University of Nottingham	NULL	Withdrawn	18 Years	60 Years	Both	0	Phase 2	United Kingdom